What Else GLP-1 Drugs Do, Beyond Weight Loss

GLP-1s were approved for diabetes, then for weight management — but the trial evidence has kept expanding into organ systems that have nothing to do with the number on a scale. Four large outcome trials now show measurable benefit to the heart, the kidneys, and breathing during sleep. That evidence changes what you're actually protecting by staying on treatment.

The heart: a 20% relative reduction in major cardiovascular events

The SELECT trial enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, but without diabetes, and followed them for a mean of nearly 40 months. A primary cardiovascular event — death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke — occurred in 6.5% of the semaglutide group versus 8.0% on placebo, a hazard ratio of 0.80¹. That's a real, statistically robust reduction in the events that actually kill people with heart disease, independent of a diabetes diagnosis.

The kidneys: a 24% lower risk of kidney failure and cardiovascular death

The FLOW trial tested semaglutide specifically in 3,533 people with type 2 diabetes and chronic kidney disease. The trial was stopped early, at a prespecified interim analysis, because the benefit was already clear: the risk of the primary composite outcome — kidney failure, a substantial drop in kidney function, or death from kidney or cardiovascular causes — was 24% lower in the semaglutide group (hazard ratio 0.76, 95% CI 0.66–0.88, P = 0.0003)². For people managing both diabetes and declining kidney function, that's not a side benefit of weight loss — it's a direct, trial-proven organ-protective effect.

Sleep apnea: tirzepatide earned its own FDA indication for it

The SURMOUNT-OSA trials tested tirzepatide specifically in adults with moderate-to-severe obstructive sleep apnea and obesity. In the arm not already using positive airway pressure therapy, tirzepatide reduced the apnea-hypopnea index by an estimated 20.0 events per hour more than placebo at 52 weeks³ — a large enough effect that the FDA added obstructive sleep apnea to Zepbound's approved indications, covered in more depth in Mounjaro vs. Zepbound This isn't a side effect of weight loss dressed up as a new use; it's a specifically studied, specifically approved indication.

Heart failure with preserved ejection fraction: symptoms and function, not just weight

The STEP-HFpEF trial enrolled 529 people with heart failure with preserved ejection fraction and obesity — a form of heart failure with few effective treatments — and randomized them to semaglutide or placebo for 52 weeks. Semaglutide improved the Kansas City Cardiomyopathy Questionnaire symptom score by 7.8 points more than placebo and increased six-minute walk distance by 20.3 meters more than placebo, alongside a −13.3% versus −2.6% weight change⁴. Fewer symptoms and better functional capacity, measured directly — not inferred from the scale.

Why this changes what "stopping" actually costs

Our weight-regain evidence already covers what the trials show happens to your weight when you stop a GLP-1. This is the other half of that decision: every trial above measured *ongoing* treatment against placebo, over months to years — the cardiovascular, kidney, sleep-apnea, and heart-failure benefits are functions of continued therapy, not a one-time reset you bank and walk away from. If you have a relevant comorbidity, stopping isn't just a weight question anymore.

Where this belongs in a provider's grade

A provider whose prescribers can actually discuss these trial-proven benefits — and, just as importantly, know when a comorbidity like heart failure or advanced kidney disease changes the monitoring plan — is demonstrating real clinical depth, not just running an intake form. That's the substance behind the clinical-oversight dimension of the WeighScore, and it's part of why our six-point checklist puts real prescriber engagement first.

The honest bottom line

GLP-1s have moved well past "weight-loss drug" in the trial record — the cardiovascular, kidney, sleep-apnea, and heart-failure evidence is real, large-scale, and specific. That expands what's actually at stake in the maintenance decision, and it's a reason to want a provider who understands the full picture, not just the scale. Compare graded providers on clinical depth in our reviews and comparisons None of this is medical advice — whether any of these benefits apply to you is a conversation for a clinician who knows your full history.